Detalles de la búsqueda
1.
Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.
Nature
; 561(7723): 406-410, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30202088
2.
Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks.
J Infect Dis
; 228(7): 907-918, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37498738
3.
Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial.
Clin Infect Dis
; 77(7): 1012-1020, 2023 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37338148
4.
The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease.
J Infect Dis
; 226(6): 1057-1068, 2022 09 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35299248
5.
Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial.
Clin Infect Dis
; 69(9): 1489-1497, 2019 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30601950
6.
Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs.
Retrovirology
; 13(1): 62, 2016 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27595568
7.
Gut commensal microbes do not represent a dominant antigenic source for continuous CD4+ T-cell activation during HIV-1 infection.
Eur J Immunol
; 45(11): 3107-13, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26345361
8.
CD8+ T cells are activated in an antigen-independent manner in HIV-infected individuals.
J Immunol
; 192(4): 1732-44, 2014 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24446519
9.
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.
J Infect Dis
; 208(7): 1102-12, 2013 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23847055
10.
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
Nat Med
; 11(6): 615-22, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15880120
11.
Detecting Selection in the HIV-1 Genome during Sexual Transmission Events.
Viruses
; 14(2)2022 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35215999
12.
Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection.
Clin Infect Dis
; 53(12): 1271-9, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21998286
13.
HIV rebounds from latently infected cells, rather than from continuing low-level replication.
Proc Natl Acad Sci U S A
; 105(43): 16725-30, 2008 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-18936487
14.
Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
J Infect Dis
; 201(7): 1063-71, 2010 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20196655
15.
A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.
Viruses
; 13(3)2021 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33806576
16.
Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.
J Acquir Immune Defic Syndr
; 88(1): 61-69, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34397744
17.
HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection.
JCI Insight
; 6(9)2021 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33784259
18.
HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia.
Clin Infect Dis
; 48(11): e117-20, 2009 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19382874
19.
Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.
J Virol
; 82(8): 3834-42, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18234794
20.
In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.
J Virol
; 82(3): 1591-9, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18032508